Amendments to the limits for harmful residues in Chinese herbal medicines and related measures for implementation in Hong Kong
The Chinese Medicines Board under the Chinese Medicine Council of Hong Kong (CMCHK) has completed the six-month public consultation (31 March 2021 to 30 September 2021) regarding proposed amendments to the limits for harmful residues in Chinese herbal medicines in Hong Kong. The consultation document and Powerpoint (Chinese version only) can be browsed on this webpage.
Amendments to the limits for harmful residues in Chinese herbal medicines and related measures for implementation in Hong Kong (Revised Proposal)
The Chinese Medicines Board under the CMCHK noted the concerns raised by the Chinese medicines trade regarding the limit of DDT residues in Radix Panacis Quinquefolii (西洋參) during the consultation. After deliberation, the Chinese Medicines Board endorsed to revise the proposed amendments to the limit of DDT residues in Radix Panacis Quinquefolii and the related measures for implementation as stipulated in the consultation document, and to further consult the trade with a consultation period of approximately three weeks. To facilitate the Chinese Medicines Board to carry out further consultation on the above revised proposal, the announcement of the finalized limits of harmful residues in Chinese herbal medicines and relevant implementation schedule will be correspondingly postponed from October 2021 as stipulated in the consultation document to December 2021.
Please click here to browse the revised consultation document. To facilitate the trade to know more about the revised proposal, a set of FAQ (Chinese version only) is prepared for trade’s reference.
Members of the Chinese medicines trade and the public are welcome to offer views on the revised proposal by post (16/F, AIA Kowloon Tower, Landmark East, 100 How Ming Street, Kwun Tong, Kowloon), by fax (2319 2664) or by email (email@example.com or firstname.lastname@example.org) on or before 10 November 2021.